ID   NCC-CC4-1
AC   CVCL_7888
DR   TKG; TKG 0745
DR   Wikidata; Q54907607
RX   CelloPub=CLPUB00275;
RX   PubMed=20088962;
RX   PubMed=26141945;
RX   PubMed=27833395;
RX   PubMed=35640676;
CC   Population: Japanese.
CC   Derived from site: In situ; Liver, intrahepatic bile duct; UBERON=UBERON_0003704.
ST   Source(s): TKG=TKG 0745
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,12
ST   D16S539: 10,13
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 16
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A8DR ! NCC-CC4-2
OI   CVCL_A8DS ! NCC-CC4-3
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 14
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=20088962; DOI=10.1111/j.1349-7006.2009.01462.x; PMCID=PMC11158935;
RA   Ojima H., Yoshikawa D., Ino Y., Shimizu H., Miyamoto M., Kokubu A.,
RA   Hiraoka N., Morofuji N., Kondo T., Onaya H., Okusaka T., Shimada K.,
RA   Sakamoto Y., Esaki M., Nara S., Kosuge T., Hirohashi S., Kanai Y.,
RA   Shibata T.;
RT   "Establishment of six new human biliary tract carcinoma cell lines and
RT   identification of MAGEH1 as a candidate biomarker for predicting the
RT   efficacy of gemcitabine treatment.";
RL   Cancer Sci. 101:882-888(2010).
//
RX   PubMed=26141945; DOI=10.1158/1535-7163.MCT-15-0069;
RA   Shirota T., Ojima H., Hiraoka N., Shimada K., Rokutan H., Arai Y.,
RA   Kanai Y., Miyagawa S., Shibata T.;
RT   "Heat shock protein 90 is a potential therapeutic target in
RT   cholangiocarcinoma.";
RL   Mol. Cancer Ther. 14:1985-1993(2015).
//
RX   PubMed=27833395; DOI=10.3748/wjg.v22.i40.9035; PMCID=PMC5083809;
RA   Ojima H., Yamagishi S., Shimada K., Shibata T.;
RT   "Establishment of various biliary tract carcinoma cell lines and
RT   xenograft models for appropriate preclinical studies.";
RL   World J. Gastroenterol. 22:9035-9038(2016).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//